Dual immunotherapy – nivolumab (Opdivo) plus ipilimumab (Yervoy) – will be PBS listed from July 1 for first-line treatment of unresectable malignant mesothelioma. Evidence for the combination immunotherapy came from the CheckMate-743 trial which found nivolumab plus ipilimumab improved overall survival compared to standard of care chemotherapy (18·1 v 14·1 months: HR 0.74; p=0.002). The ...
Nivolumab + ipilimumab on the PBS for mesothelioma
By Mardi Chapman
24 Jun 2021